Concord Biotech Ltd (CONCORDBIO)
₹1,460.00
Mkt cap
₹15,098 Cr
P/E ratio
53.10
P/B
7.56
Div yield
0.52%
ROE
12.60%
ROCE
17.40%
EPS (TTM)
₹27.50
Book value
₹193
52W range
1,015–1,699
Sector
Healthcare
Price history
Previous close
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. [1]
NSE CONCORDBIOBSE 543960
Health check
Constructive
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−14.06% from high₹1,460
₹1,015+43.87% from low₹1,699
Current
₹1,460.00
Prev close
₹1,449.90
Day
+0.70%
Price performance
1D
+0.70%
1W
−1.64%
1M
+2.89%
3M
+9.72%
6M
+21.29%
1Y
−13.54%
YTD
+11.32%
Financials
Revenue, profit & margin
P/E ratio
53.1×
CONCORDBIO is 51% above the sector median of 35.1×
CONCORDBIO53.1×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 | 278 | 326 | 261 | |
| Expenses | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 | 176 | 204 | 173 | |
| Operating Profit | 72 | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 | 102 | 122 | 87 | |
| OPM % | 37% | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% | 37% | 38% | 33% | |
| Other Income | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 | 7 | 16 | 13 | |
| Interest | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 | 19 | 19 | 18 | |
| Profit before tax | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 | 90 | 118 | 82 | |
| Tax % | 25% | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% | 25% | 24% | 26% | |
| Net Profit | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 | 68 | 90 | 61 | |
| EPS in Rs | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 | 6.48 | 8.60 | 5.85 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.20% · closed higher next day 5 of last 13
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23 | 9 Feb '24 | 24 May '24 | 9 Aug '24 | 12 Nov '24 | 14 Feb '25 | 29 May '25◦ | 8 Aug '25◦ | 13 Nov '25◦ | 11 Feb '26◦ | 29 May '26◦ | 31 Jul '26◦ |
| Earnings day | +4.03% | −1.23% | −0.52% | −2.01% | −1.10% | −19.86% | +4.90% | +0.38% | +2.77% | −1.28% | +0.96% | −0.44% |
| +1 day | −1.66% | −2.66% | −1.26% | −4.72% | −1.55% | −20.33% | +9.15% | +3.15% | +2.98% | −4.85% | +10.94% | −0.06% |
| +5 days | −3.35% | −0.77% | +0.29% | +3.57% | +5.75% | −21.85% | +15.58% | +3.05% | −2.13% | −10.24% | +13.84% | −0.13% |
| +15 days | +1.50% | +0.24% | +4.89% | +9.40% | +16.75% | −20.58% | +10.22% | +6.31% | −3.45% | −3.02% | +27.25% | +8.35% |
| +30 days | +13.71% | +1.49% | +15.76% | +50.26% | +14.99% | −19.66% | +8.18% | +1.98% | −8.40% | −18.19% | +26.29% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 7.55 Per Share | 7.55 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Jun 202644.08%Promoter
Promoters44.08%
FIIs7.53%0.26
DIIs9.37%0.15
Public39.04%0.14
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| CONCORDBIO | ₹1,443.20 | 53.10 | 15,098 | 0.52% | 61 | +43.74% | 261 | +27.71% | 17.43% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Concall transcripts30
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptJun 2026PPTJun 2026RECJun 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJun 2024PPTJun 2024TranscriptFeb 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Aug - The officials of the Company will be attending an Investor Conference on 26th August 2026 as per the schedule and details in the file uploaded …Announcement under Regulation 30 (LODR)-Earnings Call Transcript 7 Aug - Transcript of Q1 - FY27 Earnings call held on August 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 3 Aug - Q1 FY27 earnings call recording hosted on company website after August 3, 2026 call.Announcement under Regulation 30 (LODR)-Investor Presentation 1 Aug - Investors'' Presentation on unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 1 Aug